Adverum Biotechnologies, Inc. (ADVM)
Dec 9, 2025 - ADVM was delisted (reason: acquired by LLY)
4.360
+0.100 (2.35%)
Inactive · Last trade price on Dec 8, 2025
Adverum Biotechnologies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 26.06 | 60.65 | 75 | 68.43 | 34.2 | 62.42 |
Short-Term Investments | - | 65.04 | 21.53 | 117.16 | 270.99 | 367.31 |
Cash & Short-Term Investments | 26.06 | 125.69 | 96.53 | 185.59 | 305.19 | 429.73 |
Cash Growth | -82.99% | 30.21% | -47.99% | -39.19% | -28.98% | 158.82% |
Receivables | - | - | - | - | 5.71 | - |
Prepaid Expenses | 2.85 | 5.61 | 6.25 | 5.01 | 6.25 | 4.71 |
Total Current Assets | 28.91 | 131.3 | 102.77 | 190.6 | 317.15 | 434.44 |
Property, Plant & Equipment | 39.49 | 45.22 | 49.79 | 113.86 | 119.06 | 47.1 |
Other Long-Term Assets | 4 | 3.32 | 3.21 | 3.92 | 3.52 | 1.03 |
Total Assets | 72.4 | 179.84 | 155.77 | 308.37 | 439.73 | 482.57 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 12.46 | 1.61 | 1.92 | 2.24 | 1.39 | 2.81 |
Accrued Expenses | 25.58 | 14.5 | 11.76 | 16.1 | 14.71 | 12.26 |
Current Portion of Leases | 5.81 | 5.67 | 5.48 | 13.24 | 1.89 | 4.47 |
Current Income Taxes Payable | - | 0.12 | 0.1 | 0.25 | 1.32 | 0.04 |
Other Current Liabilities | 0.9 | 1 | 0.73 | 0.42 | 2.02 | 1.29 |
Total Current Liabilities | 44.75 | 22.9 | 19.98 | 32.25 | 21.32 | 20.87 |
Long-Term Leases | 83.13 | 86.04 | 68.57 | 93.56 | 101.11 | 26.24 |
Other Long-Term Liabilities | 0.18 | 0.19 | - | 1.05 | 1.11 | 1.11 |
Total Liabilities | 128.05 | 109.13 | 88.55 | 126.85 | 123.54 | 48.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 1,156 | 1,138 | 1,004 | 985.65 | 964.97 | 937.13 |
Retained Earnings | -1,211 | -1,067 | -936.02 | -802.61 | -648.08 | -502.54 |
Comprehensive Income & Other | -0.44 | -0.41 | -0.47 | -1.53 | -0.71 | -0.26 |
Shareholders' Equity | -55.65 | 70.71 | 67.22 | 181.52 | 316.19 | 434.35 |
Total Liabilities & Equity | 72.4 | 179.84 | 155.77 | 308.37 | 439.73 | 482.57 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 88.94 | 91.71 | 74.04 | 106.8 | 102.99 | 30.71 |
Net Cash (Debt) | -62.88 | 33.99 | 22.49 | 78.79 | 202.19 | 399.02 |
Net Cash Growth | - | 51.15% | -71.46% | -61.03% | -49.33% | 198.47% |
Net Cash Per Share | -2.91 | 1.72 | 2.23 | 7.94 | 20.62 | 46.86 |
Filing Date Shares Outstanding | 22.08 | 20.89 | 20.75 | 10.06 | 9.88 | 9.78 |
Total Common Shares Outstanding | 22 | 20.85 | 10.14 | 10.01 | 9.84 | 9.75 |
Working Capital | -15.84 | 108.4 | 82.79 | 158.35 | 295.83 | 413.57 |
Book Value Per Share | -2.53 | 3.39 | 6.63 | 18.13 | 32.14 | 44.53 |
Tangible Book Value | -55.65 | 70.71 | 67.22 | 181.52 | 316.19 | 434.35 |
Tangible Book Value Per Share | -2.53 | 3.39 | 6.63 | 18.13 | 32.14 | 44.53 |
Machinery | 15.41 | 15.86 | 15.51 | 16.58 | 15.14 | 11.21 |
Construction In Progress | 0.02 | 0.01 | 0.18 | 1.01 | 4.4 | 1.95 |
Leasehold Improvements | 13.78 | 13.78 | 13.59 | 34.34 | 26.7 | 24.63 |